Thalidomide, an antiangiogenic agent with clinical activity in cancer

被引：21

作者：

Ng, SSW ^{[1
]}

Brown, M ^{[1
]}

Figg, WD ^{[1
]}

机构：

[1] Natl Canc Inst, Mol Pharmacol Sect, Canc Therapeut Branch, Ctr Canc Res,NIH, Bethesda, MD 20892 USA

来源：

BIOMEDICINE & PHARMACOTHERAPY | 2002年 / 56卷 / 04期

关键词：

thalidomide; HIV-infection; bFGF; VEGF;

D O I：

10.1016/S0753-3322(02)00177-4

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Despite the teratogenic past of thalidomide, there is recent evidence indicating the drug's efficacy in the management of various diseases from immune disorders to cancers. The history, pharmacodynamic and pharmacokinetic properties of thalidomide in the clinic are discussed in this review article. (C) 2002 Editions scientifiques et medicales Elsevier SAS.

引用

页码：194 / 199

页数：6

共 46 条

[31]

PATT YZ, 2000, P AN M AM SOC CLIN, V19, P266

[32] Potential novel uses of thalidomide - Focus on palliative care [J].

Peuckmann, V ;

Fisch, M ;

Bruera, E .

DRUGS, 2000, 60 (02) :273-292

[33]

QUILITZ R, 1999, JMCC, V6, P483

[34]

RAJKUMAR S, 2000, BLOOD, V96, P168

[35] Thalidomide in the treatment of relapsed multiple myeloma [J].

Rajkumar, SV ;

Fonseca, R ;

Dispenzieri, A ;

Lacy, MQ ;

Lust, JA ;

Witzig, TE ;

Kyle, RA ;

Gertz, MA ;

Greipp, PR .

MAYO CLINIC PROCEEDINGS, 2000, 75 (09) :897-901

[36]

Rajkumar SV, 2001, J CLIN ONCOL, V19, P3593

[37] Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells [J].

Rowland, TL ;

McHugh, SM ;

Deighton, J ;

Dearman, RJ ;

Ewan, PW ;

Kimber, I .

IMMUNOPHARMACOLOGY, 1998, 40 (01) :11-20

[38] THALIDOMIDE SELECTIVELY INHIBITS TUMOR-NECROSIS-FACTOR-ALPHA PRODUCTION BY STIMULATED HUMAN MONOCYTES [J].

SAMPAIO, EP ;

SARNO, EN ;

GALILLY, R ;

COHN, ZA ;

KAPLAN, G .

JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 173 (03) :699-703

[39] THALIDOMIDE INCREASES THE SYNTHESIS OF IL-2 IN CULTURES OF HUMAN MONONUCLEAR-CELLS STIMULATED WITH CONCANAVALIN-A, STAPHYLOCOCCAL-ENTEROTOXIN-A, AND PURIFIED PROTEIN DERIVATIVE [J].

SHANNON, EJ ;

SANDOVAL, F .

IMMUNOPHARMACOLOGY, 1995, 31 (01) :109-116

[40] The treatment of advanced renal cell cancer with high-dose oral thalidomide [J].

Stebbing, J ;

Benson, C ;

Eisen, T ;

Pyle, L ;

Smalley, K ;

Bridle, H ;

Mak, I ;

Sapunar, F ;

Ahern, R ;

Gore, ME .

BRITISH JOURNAL OF CANCER, 2001, 85 (07) :953-958

← 1 2 3 4 5 →